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ABSTRACT
Severe acute kidney injury (AKI), defined as requiring renal replacement
therapy (RRT), is associated with higher mortality postheart transplanta-
tion, but its long-term renal consequences are not known. Anonymized
data of 3365 patients, who underwent heart transplantation between 1995
and 2017, were retrieved from the UK Transplant Registry. Multivariable
binary logistic regression was performed to identify risk factors for severe
AKI requiring RRT, Kaplan–Meier analysis to compare survival and renal
function deterioration of the RRT and non-RRT groups, and multivariable
Cox regression model to identify predicting factors of mortality and end-
stage renal disease (ESRD). 26.0% of heart recipients received RRT post-
transplant. The RRT group has lower survival rates at all time points, espe-
cially in the immediate post-transplant period. However, conditional on
3 months survival, older age, diabetes and coronary heart disease, but not
post-transplant RRT, were the risk factors for long-term survival. The pre-
dicting factors for ESRD were insulin-dependent diabetes, renal function at
transplantation, eGFR decline in the first 3 months post-transplant, post-
transplant severe AKI and transplantation era. Severe AKI requiring RRT
post-transplant is associated with worse short-term survival, but has no
impact on long-term mortality. It also accelerates recipients’ renal function
deterioration in the long term.
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Introduction
Heart transplantation is the gold standard treatment for
selected patients with end-stage heart failure. Survival of
heart transplant recipients worldwide has increased sig-
nificantly in the past few decades [1], but long-term
complications remain a concern.
Chronic kidney disease (CKD) is one of the common
noncardiac complications experienced by heart trans-
plant recipients. The incidence of CKD reported previ-
ously varies widely because of the usage of different
definitions, study types and follow-up periods [2–5]. All
of the studies agreed that CKD has an adverse impact
on recipients’ survival and quality of life [2–5]. Hence,
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT 1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
doi:10.1111/tri.13675
Transplant International
it is crucial for clinicians to recognize, quantify, prevent
and manage the risk factors contributing to CKD.
Prior to heart transplantation, the majority of patients
on the waiting list have a degree of renal impairment [6],
caused by a combination of reduced renal perfusion, fluid
restriction, use of diuretics and renin–angiotensin–aldos-
terone system inhibitors, and comorbidities, such as dia-
betes mellitus and hypertension. Post-transplant,
nephrotoxic calcineurin inhibitors are thought to be the
main cause of renal function decline [2,4,7]. However, lit-
tle is known about the impact of the events occurring at
the peri-operative stage on the long-term renal function
of heart transplant recipients.
In general population [8] and nontransplant postcar-
diac surgery patients [9,10], an episode of acute kidney
injury (AKI) leads to an increased risk of mortality and
developing CKD in the future. Only a few studies have
looked at this problem in heart transplant recipients
and identified severe AKI as a contributing factor to
poorer outcomes [2,11,12]. To better understand the
role of severe AKI, defined as the Kidney Disease:
Improving Global Outcomes (KDIGO) classification
stage 3 AKI requiring renal replacement therapy (RRT)
within 30 days post-transplant, we used the UK Trans-
plant Registry data to (i) identify the predictors of stage
3 AKI requiring RRT; (ii) study its impact on recipi-
ents’ survival; and (iii) investigate its influence on recip-
ient’s long-term renal function.
Methods
Study design
This is a national multi-centre retrospective cohort
study. All patients aged 16 years and older, undergoing
heart transplantation between April 1995 and March
2017 in the UK, were included. Multi-organ transplants
were excluded. Recipient and donor characteristics,
operation details and post-transplant outcomes were
collected from the UK Transplant Registry, which is
maintained by the National Health Service Blood and
Transplant (NHSBT). It captures all of the transplant
activities across the UK, as data submission is manda-
tory. All the data in the registry have been validated. As
this project did not involve patient identifiable informa-
tion, a separate research ethics committee approval was
not required [13].
Recipients’ data included age, sex, ethnicity, pretrans-
plant diabetes status, hypertension, cardiac pathology,
urgency status for transplantation, pretransplant haemo-
dynamic support, namely ventricular assist device
(VAD), inotrope, intra-aortic balloon pump (IABP),
and extra-corporeal membrane oxygenation (ECMO)
prior to transplantation, and peri-transplant renal func-
tion. The peri-transplant renal function was measured
as serum creatinine (SCr) immediately before the trans-
plant operation, 3 and 12 months post-transplant, and
annually afterwards. The estimated glomerular filtration
rate (eGFR) was calculated using the Modification of
Diet in Renal Disease 4-variable equation [14]. Based
on the eGFR, recipients’ renal function was assigned to
one of the National Kidney Foundation (NKF) chronic
kidney disease (CKD) stages [15]. DeGFR was the dif-
ference in the eGFRs at transplantation and 3 months
post-transplant. End-stage renal disease (ESRD) was
defined as NKF CKD stage 5 (eGFR < 15 ml/min/
1.37 m2), or being listed for or received renal transplan-
tation. Donors’ data consisted of donor age and sex.
The operation details were transplantation date, centre
and allograft total ischaemic time. Transplants were cat-
egorized into four eras, namely era 1995–2000, era
2001–2005, era 2006–2010 and era 2011–2017, to study
the changes in transplantation practice over time. The
post-transplant outcomes were RRT within 30 days
post-transplant, re-exploration, infection, and require-
ment of IABP and other mechanical assistance, recipi-
ents’ survival status and length, and development of
ESRD. In the registry data collection, the term RRT
refers to both haemofiltration and haemodialysis.
Statistical analysis
The recipient cohort was divided into two groups, based
on whether they developed severe AKI requiring RRT
within 30-day post-transplant. To compare the means
of continuous variables, Mann–Whitney U-test and
two-sample t-test were used when appropriate. Chi-
squared test was applied to compare frequencies of sub-
groups and test associations of categorical variables.
To identify the factors associated with RRT usage, uni-
variable binary logistic regression was performed for the
donor- and recipient-related variables, operative details,
and development of post-transplant severe primary graft
dysfunction (PGD). All factors with P < 0.1 were entered
into the multivariable binary logistic regression.
Kaplan–Meier (KM) analysis was performed to com-
pare the survival and freedom from ESRD post-trans-
plant of the RRT and non-RRT groups. Multivariable
Cox regression models for time to death and time to
develop ESRD, in recipients who survived for at least
3 months post-transplant, were used to identify the
respective predicting factors. 477 patients who did not
2 Transplant International 2020;
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Wang et al.
survive beyond 3-month post-transplant and 56 patients
with missing survival information were excluded from
the analysis. The time point of 3 months was chosen
because the survival behaviour of both RRT and non-
RRT groups was very different before and after this time
point. Also, 3 months is when the UK Transplant Regis-
try records the first follow-up renal function. In addi-
tion, RRT and its interaction with transplantation era
were included in the Cox model. The hazard ratios
(HR) of the RRT group of era 2001–2005, era 2006–
2010 and era 2011–2017 were calculated by the HR of
era 1995–2000, 1.34, multiplied by the HRs of the non-
RRT group and the interaction between era and RRT in
the corresponding era, respectively. A step-down
method guided by Akaike information criteria was used
for model selection. Missing data were replaced by mul-
tiple imputation.
A subgroup analysis of the 361 recipients, who devel-
oped severe PGD, including severe PGD-left ventricle
(LV) and PGD-right ventricle (RV), defined by the
International Society for Heart and Lung Association
Classification for PGD [16], was performed. A multi-
variable binary logistic regression was used to identify
the predictors of death within 90 days post-transplant.
All statistical analyses were undertaken using the R
programming language version 3.2.5 and IBM SPSS Statis-
tics version 24 64-bit edition.
Results
Baseline characteristics
A total of 3365 patients aged 16 years and older under-
went heart transplantation in eight centres during this
22-year period. The cohort was 77.3% male, with a
mean age of 46.7  12.8 years. 26.0% (876/3365) recip-
ients required RRT within 30 days post-transplant.
Table 1 summarizes the recipient characteristics and
operation details of the cohort.
Table 1. Recipient and donor characteristics and
operation details of the 3365 heart transplantations.
N = 3365
Donor sex
Female 1136 (33.8)
Male 2228 (66.2)
Donor age (year) 36.3  12.4
Recipient sex
Table 1. Continued.
N = 3365
Female 763 (22.7)
Male 2601 (77.3)
Recipient age (year) 46.7  12.8
Gender mismatch
No 2457 (73.0)
Male donor to female recipient 268 (8.0)
Female donor to male recipient 639 (19.0)
Recipient ethnicity
Asian 192 (5.8)
Black 56 (1.7)
White 3034 (91.6)
Others 30 (0.9)
Recipient diabetes status at registration
No 2920 (91.0)
Yes, insulin dependent 124 (3.9)
Yes, noninsulin dependent 164 (5.1)
Recipient hypertension at registration
No 2597 (81.3)
Yes 597 (18.7)
Recipient preop cardiac pathology
Congenital heart disease 175 (5.2)
Coronary artery disease 948 (28.4)
Dilated cardiomyopathy 1674 (50.1)
Others 545 (16.3)
Recipient renal function at transplantation
eGFR ≥ 60 ml/min/1.73 m2 1682 (54.9)
CKD Stage 3 1278 (41.7)
CKD Stage 4 95 (3.1)
CKD Stage 5 11 (0.3)
Urgent status recipient at transplantation 1009 (30.0)
Recipient with VAD prior to transplantation
None 1878 (85.5)
Left VAD 160 (7.3)
Right VAD 27 (1.2)
Bilateral VAD 132 (6.0)
Recipient on inotrope prior to transplantation 895 (41.5)
Recipient on IABP prior to transplantation 230 (10.5)
Recipient on ECMO prior to transplantation 28 (1.3)
Allograft total ischaemic time (h) 3.3  1.1
Transplantation era
Era 1995–2000 1330 (39.5)
Era 2001–2005 650 (19.3)
Era 2006–2010 501 (14.9)
Era 2011–2017 884 (26.3)
Transplantation centre
Centre 1 520 (15.6)
Centre 2 107 (3.2)
Centre 3 808 (24.2)
Centre 4 613 (18.3)
Centre 5 131 (3.9)
Centre 6 438 (13.1)
Centre 7 427 (12.8)
Centre 8 300 (8.9)
Data are given as number (percentage) or mean  SD, as
appropriate.
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Renal replacement therapy usage had steadily
increased from 12.0% (158/1312) in the era 1995–2000
to 47.7% (410/859) in the era 2011–2017. This temporal
trend was observed across all centres (Fig. 1). The
increase of RRT usage over time was accompanied by
the rise in donor age, and recipients of urgent status
and being supported by VAD, inotrope, IABP and
ECMO prior to transplantation (Table 2). Moreover,
RRT usage varied across centres, ranging from 4.7% (5/
107) to 35.4% (217/613; Table 3).
Risk factors of severe AKI requiring RRT post-
transplant
The results of the binary logistic regression, which
aimed to identify variables predicting post-transplant
RRT, were displayed in Table 4. With other factors con-
trolled, male recipients [odds ratio (OR) 1.80, 95% con-
fidence interval (CI): 1.33–2.43] were more likely to
require RRT. The other recipient-related risk factors for
RRT were requiring left VAD (OR 1.94, 95% CI: 1.22–
3.08) and inotrope (OR 1.42, 95% CI: 1.05–1.92) prior
to transplantation, renal function at the time of trans-
plantation and development of severe PGD (OR 7.17,
95% CI: 4.99–10.30) post-transplant. Moreover, grafts
from older donors increased the risk of RRT (OR 1.02,
95% CI: 1.01–1.03). Furthermore, RRT usage steadily
increased with time, with the ORs for the latter three
eras being 2.68 (95% CI: 1.69–4.26), 4.76 (95% CI:
2.94–7.70) and 7.66 (95% CI: 4.71–12.44), respectively.
Moreover, recipients treated in centres 4 (OR 2.10, 95%
CI: 1.38–3.19) were significantly more likely to receive
Figure 1 The percentage of recipients who developed stage 3 AKI requiring RRT post-transplant in the individual centres across the eras.
Table 2. Changes of donor and recipient characteristics across transplantation eras.
Era 1995–2000
N = 1330
Era 2001–2005
N = 650
Era 2006–2010
N = 501
Era 2011–2017
N = 884
Donor age (year), mean  SD 34.2  12.2 36.3  12.3 37.1  12.0 39.1  12.4
Recipient age (year), mean  SD 48.6  10.9 45.5  13.5 45.1  13.6 45.6  13.9
Urgent status recipient at transplantation 22/1330 (1.7) 136/650 (20.9) 196/501 (39.1) 655/884 (74.1)
Recipient with VAD prior to transplantation
None 658/676 (97.3) 363/415 (87.5) 289/352 (82.1) 568/754 (75.3)
Left VAD 11/676 (1.6) 28/415 (6.7) 25/352 (7.1) 96/754 (12.7)
Right VAD 1/676 (0.1) 3/415 (0.7) 7/352 (2.0) 16/754 (2.1)
Bilateral VAD 6/676 (0.9) 21/415 (5.1) 31/352 (8.8) 74/754 (9.8)
Recipient on inotrope prior to transplantation 161 /671 (24.0) 165/403 (40.9) 138/350 (39.4) 431/735 (58.6)
Recipient on IABP prior to transplantation 52/678 (7.7) 56/411 (13.6) 55/353 (15.6) 67/741 (9.0)
Recipient on ECMO prior to transplantation 0/677 (0) 5/411 (1.2) 5/352 (1.4) 18/740 (2.4)
Allograft total ischaemic time (h), mean  SD 3.0  1.0 3.6  0.9 3.5  0.9 3.3  1.4
Data are given as number (percentage) or mean  SD, as appropriate.
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RRT, while recipients in centre 3 (OR 0.64, 95% CI:
0.42–0.98) were less likely.
Association between post-transplant complications
and severe AKI requiring RRT
All of the recorded post-transplant complications,
including re-exploration (OR 6.65, 95% CI: 5.55–7.96),
infection (OR 3.07, 95% CI: 2.56–3.70), and require-
ment of IABP (OR 5.65, 95% CI: 4.71–6.79) and other
mechanical support (OR 11.66, 95% CI: 9.02–15.06)
were significantly associated with severe AKI requiring
RRT (Table 5).
Survival analysis
Figure 2 shows the KM survival curves of the RRT and
non-RRT groups. At all time points post-transplant, the
survival rates of the RRT group were lower than that of
the non-RRT group. The most-striking difference
occurred in the immediate post-transplant period. The
30-day survival was 94.7% (95% CI: 93.8–95.6%) for
the non-RRT group, but only 71.6% (95% CI: 68.7–
74.7%) for the RRT group. The majority of the early
deaths occurred within the first 3 months.
A multivariable Cox regression model of time to
death was then used to identify factors associated with
median-term and long-term survival, conditional on
3 months post-transplant survival (Table 6). Older
recipient age (HR 1.01, 95% CI: 1.00–1.02), and both
insulin-dependent (HR 1.54, 95% CI: 1.17–2.00) and
non-insulin-dependent diabetes (HR 1.34, 95% CI:
1.03–1.75) were statistically significant predictors of sur-
vival post-transplant. Compared to those with congeni-
tal heart disease, recipients with coronary artery disease
had increased risk of mortality (HR 1.62, 95% CI: 1.07–
2.50). Survival rate differences across centres were gen-
erally not significant. Postoperative RRT, renal func-
tional at transplantation and DeGFR did not have an
adverse impact on long-term survival for patients who
survived for at least 3 months post-transplant. There
was a general trend of improvement in overall survival
over time. For example, compared to the recipients of
the non-RRT group in era 1995–2000, those recipients
of the non-RRT group (HR 0.71, 95% CI: 0.54–0.92)
and RRT group (HR 0.72) in era 2006–2010 had signifi-
cantly better survival. A similar HR was observed in the
non-RRT group in era 2011–2017 (HR 0.74, 95% CI:
0.52–1.04), though not at a statistically significant level,
which was probably because of a shorter follow-up
duration and smaller number of events in this group.T
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Table 4. Binary logistic regression for risk factors associated with post-transplant RRT.
Univariate analysis Multivariate analysis
N Odds Ratio P-value Odds Ratio 95% CI P-value
Donor sex
Female 1136 1.00 –
Male 2228 0.99 0.9
Donor age 3365 1.02 <0.001 1.02 1.01–1.03 0.001
Recipient sex
Female 763 1.00 – 1.00 – –
Male 2601 1.10 <0.001 1.80 1.33–2.43 <0.001
Recipient age 3365 1.00 0.9
Gender mismatch
No 2457
Male donor to female recipient 268 1.05 0.7
Female donor to male recipient 639 1.09 0.4
Recipient ethnicity
Asian 192 1.00 –
Black 56 1.03 0.7
White 3034 0.98 0.5
Others 30 0.97 0.7
Recipient diabetes status at registration
No 2920 1.00 –
Yes, insulin dependent 124 1.01 0.8
Yes, noninsulin dependent 164 0.99 0.7
Recipient hypertension at registration
No 2597 1.00 –
Yes 597 1.01 0.5
Recipient preop cardiac pathology
Congenital heart disease 175 1.00 – 1.00 – –
Coronary artery disease 948 0.93 0.08 0.68 0.37–1.23 0.2
Dilated cardiomyopathy 1674 0.93 0.09 0.66 0.38–1.15 0.1
Others 545 0.96 0.4 1.08 0.59–1.97 0.8
Recipient renal function at transplantation
eGFR ≥ 60 ml/min/1.73 m2 1680 1.00 – 1.00 – –
CKD Stage 3 1278 1.13 <0.001 2.21 1.71–2.86 <0.001
CKD Stage 4 95 1.27 <0.001 3.28 1.66–6.51 0.001
CKD Stage 5 11 1.41 0.07 7.13 1.17–43.64 0.03
Urgent status recipient at transplantation 1009 2.84 <0.001 0.84 0.59–1.20 0.3
Recipient with VAD prior to transplantation
None 1878 1.00 – 1.00 – –
Left VAD 160 3.94 <0.001 1.94 1.22–3.08 <0.001
Right VAD 27 2.56 0.02 1.52 0.55–4.25 0.3
Bilateral VAD 132 2.09 <0.001 1.25 0.76–2.05 0.4
Recipient on inotrope prior to transplantation 895 1.53 <0.001 1.42 1.05–1.92 0.02
Recipient on IABP prior to transplantation 230 0.97 0.9
Recipient on ECMO prior to transplantation 28 5.70 <0.001 1.83 0.66–5.06 0.2
Allograft total ischaemic time 3231 1.02 0.006 1.11 0.99–1.24 0.07
Post-transplant severe PGD 3303 11.66 <0.001 7.17 4.99–10.30 <0.001
Transplantation era
Era 1995–2000 1330 1.00 – 1.00 – –
Era 2001–2005 650 1.11 <0.001 2.68 1.69–4.26 <0.001
Era 2006–2010 501 1.22 <0.001 4.76 2.94–7.70 <0.001
Era 2011–2017 884 1.46 <0.001 7.66 4.71–12.44 <0.001
Transplantation centre
Centre 1 520 1.00 – 1.00 – –
Centre 2 107 0.99 0.8 0.25 0.03–1.95 0.2
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The characteristics of these 3-month survivors in the
RRT and non-RRT groups were summarized in Table 7.
The mean donor age of the RRT group was 2.8 years
older, while the recipient age was comparable. The RRT
group had more male patients (81.3% vs. 77.0%) and
fewer patients with ischaemic cardiomyopathy (20.0%
vs. 29.9%). The RRT group had worse renal function at
transplantation, but similar percentages of other comor-
bidities, as the non-RRT group.
Among the whole cohort, 361 (10.9%) recipients
developed severe PGD post-transplant. The percentages
of the documented severe PGD increased with time,
being 3.6% (47/1312), 10.8% (70/647), 13.7% (67/488)
and 20.7% (177/856) in the four eras, respectively.
Table 4. Continued.
Univariate analysis Multivariate analysis
N Odds Ratio P-value Odds Ratio 95% CI P-value
Centre 3 808 0.94 0.02 0.64 0.42–0.98 0.04
Centre 4 613 1.13 <0.001 2.10 1.38–3.19 <0.001
Centre 5 131 1.14 0.01 2.05 0.76–5.56 0.2
Centre 6 438 1.03 0.2 1.00 0.67–1.50 0.9
Centre 7 427 1.07 0.01 1.52 0.98–2.38 0.06
Centre 8 300 0.98 0.6 0.89 0.53–1.48 0.6
Table 5. Association between post-transplant complications and severe AKI requiring RRT.
Complications
RRT group n (%)
N = 876
Non-RRT group n (%)
N = 2429 OR 95% CI P-value
Return to theatre 415 (47.4) 290 (12.0) 6.65 5.55–7.96 <0.001
Infection 289 (34.7) 330 (14.7) 3.07 2.56–3.70 <0.001
Requirement of haemodynamic support
IABP 369 (42.5) 280 (11.5) 5.65 4.71–6.79 <0.001
Other mechanical support 268 (30.8) 89 (3.7) 11.66 9.02–15.06 <0.001
Time 30-day 1-year 5-year 10-year 15-year 20-year
Non-RRT Probability 
(95% CI)
94.7%
(93.8–95.6%)
89.2%
(88.0–90.5%)
78.4%
(76.7–80.1%)
63.8%
(61.7–65.9%)
47.4%
(45.0–49.8%)
31.5%
(28.9–34.4%)
RRT Probability 
(95% CI)
71.6%
(68.7–74.7%)
59.8%
(56.6–63.2%)
50.7%
(47.2–54.4%)
42.1%
(38.2–46.4%)
33.9%
(29.2–39.3%)
27.7%
(21.4–35.9%)
Figure 2 Kaplan–Meier survival curves and survival rates for the heart transplant recipients in the non-RRT and RRT groups.
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Table 6. Multivariate Cox regression model for time to death in patients who survived at least 3 months post-
transplant.
N
Multivariate analysis Final model
Hazard Ratio P-value Hazard Ratio 95% CI P-value
Recipient sex
Female 627 1.00 –
Male 2204 1.03 0.7
Recipient age 2832 1.01 0.02 1.01 1.00–1.02 0.005
Recipient ethnicity
Asian 159 1.00 –
Black 50 2.10 0.01
White 2549 1.47 0.03
Others 27 1.55 0.3
Recipient diabetes status at registration
No 2487 1.00 – 1.0 – –
Yes, insulin dependent 100 1.56 0.004 1.54 1.17–2.00 0.002
Yes, noninsulin dependent 131 1.30 0.08 1.34 1.03–1.75 0.03
Recipient hypertension at registration
No 2215 1.00 –
Yes 490 0.99 0.9
Recipient preop cardiac pathology
Congenital heart disease 134 1.00 –
Coronary artery disease 786 1.93 0.01 1.62 1.07–2.50 0.02
Dilated cardiomyopathy 1462 1.40 0.2 1.18 0.78–1.77 0.4
Others 435 1.75 0.03 1.44 0.94–2.20 0.09
Recipient renal function at transplantation
eGFR ≥ 60 ml/min/1.73 m2 1465 1.00 –
CKD Stage 3 1062 0.91 0.2
CKD Stage 4 67 1.01 1
CKD Stage 5 3 2.80 0.3
Allograft total ischaemic time 2724 0.97 0.4
Recipient DeGFR 2576 1.00 0.4
RRT 552
Era 1995–2000
Non-RRT 1030 1.00 – 1.00 – –
RRT 66 1.22 0.3 1.34 0.95–1.87 0.09
Era 2001–2005
Non-RRT 464 1.06 0.5 0.99 0.84–1.17 0.9
RRT 83 – – 0.92 – –
Era 2006–2010
Non-RRT 309 0.75 0.04 0.71 0.54–0.92 0.009
RRT 99 – – 0.72 – –
Era 2011–2017
Non-RRT 436 0.75 0.1 0.74 0.52–1.04 0.08
RRT 304 – – 1.51 – –
Interaction between transplantation era and RRT
Era 1995–2000 and RRT 1.00 – 1.00 – –
Era 2001–2005 and RRT 0.71 0.2 0.69 0.41–1.14 0.1
Era 2006–2010 and RRT 0.83 0.6 0.76 0.42–1.37 0.4
Era 2011–2017 and RRT 1.65 0.1 1.52 0.89–2.60 0.1
Transplantation centre
Centre 1 416 1.00 – 1.00 – –
Centre 2 98 1.02 0.9 0.90 0.65–1.24 0.5
Centre 3 713 0.92 0.4 0.88 0.72–1.09 0.2
Centre 4 489 0.82 0.1 0.81 0.64–1.01 0.06
Centre 5 101 0.94 0.7 0.94 0.69–1.28 0.7
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54.8% (198/361) of these patients died within 90 days
post-transplant. Severe AKI requiring RRT (OR 8.08,
95% CI: 2.58–25.20) was a significant risk factor of early
death in this subgroup (Table 8). Other risk factors
include older recipient age (OR 1.07, 95% CI: 1.03–
1.11), preop bilateral VAD (OR 4.91, 95% CI: 1.21–
19.97) and IABP (OR 6.30, 95% CI: 1.27–31.31), and
longer ischaemic time (OR 1.58, 95% CI: 1.12–2.22).
Renal function analysis
The recipients were also followed up in terms of their
renal function. 86.2% (2901/3365) of the patients had at
least 1 postoperative SCr documented. The median fol-
low-up time was 6 years [interquatile range (IQR): 1.6–
13.0 years].
Immediately prior to transplantation, the means of
eGFR of the RRT and non-RRT groups were compara-
ble, 67.1  32.3 and 67.9  27.3 ml/min/1.73 m2,
respectively (P = 0.5). At 3 months post-transplant, a
slightly bigger drop in eGFR was observed in the RRT
group compared to the non-RRT group (the mean
DeGFR was 13.0  37.5 and 9.3  24.3 ml/min/
1.73 m2, respectively, P = 0.026). After the initial
3 months, recipients’ renal function gradually deterio-
rated with time, as evident by the Kaplan–Meier analysis
of the freedom from development of ESRD (Fig. 3).
The time to development of ESRD was significantly
shorter for the recipients who required post-transplant
RRT. Among the patients who developed ESRD, a total
of 79 patients were registered for renal transplantation.
The median duration from the heart transplantation to
being registered for renal transplantation was 8.3 years
(IQR: 4.3–11.1 years). 60.8% (48/79) of them received
renal transplantation. The median duration from the
heart transplantation to the renal transplantation was
8.8 years (IQR: 4.4–13.2 years).
Table 9 showed the results of the multivariable Cox
regression model for time to develop ESRD in patients
who survived at least 3 months post-transplant.
Recipients with insulin-dependent diabetes at registra-
tion (HR 2.61, 95% CI: 1.44–4.81) had increased risk of
ESRD. Recipients’ renal function at transplantation was
also an independent predictor of ESRD [HR 2.12 (95%
CI: 1.45–2.90) for recipients with CKD stage 3, 4.81
(95% CI: 2.31–9.92) for CKD stage 4 and 58.03 (95%
CI: 6.32–541.01) for CKD stage 5]. A drop in the renal
function at 3 months post-transplant was associated
with a long-term deterioration in renal function, though
the effect was small (HR 1.01, 95% CI: 1.01–1.02). RRT,
recent transplantation era and the interaction between
them were significantly associated with increased proba-
bility of ESRD. Compared to the non-RRT group in the
era 1995–2000, all the non-RRT groups in the more
recent eras had much reduced risks of developing ESRD
(HR 0.44, 95% CI: 0.27–0.71 for the non-RRT group in
the era 2001–2005, HR 0.42, 95% CI: 0.19–0.92 for
those the in era 2006–2010 and HR 0.23, 95% CI: 0.05–
0.99 for those in the era 2011–2017). For the RRT
groups, the HR of developing ESRD gradually increased
with time (HR 1.16, 1.66 and 1.68 for the RRT groups
in the era 2001–2005, era 2006–2010 and era 2011–
2017, respectively). As a result, the difference between
HR of the non-RRT and RRT groups within the same
era widened with time.
There were also significant differences in the risks of
ESRD across centres. Recipients treated in centres 2, 4,
5 and 6 were at greater risk of post-transplant ESRD.
Last, interestingly, the total ischaemic time statistically
had a protective effect on the development of ESRD
(HR 0.85, 95% CI: 0.72–0.99). Other recipient-related
factors such as sex, age, ethnicity, hypertension and pre-
operative cardiac pathology did not have an effect on
renal function post-transplant.
Discussion
This study reviewed a 22-year experience of heart trans-
plantation in the UK and demonstrated that the stage 3
AKI requiring RRT within 30 days post-transplant is
Table 6. Continued.
N
Multivariate analysis Final model
Hazard Ratio P-value Hazard Ratio 95% CI P-value
Centre 6 374 1.37 0.02 1.29 1.02–1.63 0.03
Centre 7 381 1.37 0.01 1.33 1.07–1.67 0.01
Centre 8 243 1.03 0.9 0.99 0.76–1.28 0.9
DeGFR, recipient eGFR at transplantation – recipient eGFR at 3-month post-transplant.
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Table 7. Comparison of the characteristics of the patients who survived at least 3 months post-transplant in the RRT
and non-RRT groups.
RRT group
(N = 552), n (%)
Non-RRT group
(N = 2239), n (%) P-value
Donor sex
Female 178 (32.3) 737 (32.9) 0.8*
Male 373 (67.7) 1502 (67.1)
Donor age (year), mean  SD 38.0  12.3 35.2  12.4 <0.001†
Recipient sex
Female 103 (18.7) 516 (23.0) 0.03*
Male 448 (81.3) 1723 (77.0)
Recipient age (year), mean  SD 46.5  13.0 46.6  12.7 0.9†
Gender mismatch
No 404 (73.3) 1650 (73.7) 0.1*
Male donor to female recipient 37 (6.7) 184 (8.2)
Female donor to male recipient 110 (20.0) 405 (18.1)
Recipient ethnicity
Asian 40 (7.3) 113 (5.1) 0.02*
Black 16 (2.9) 34 (1.5)
White 483 (88.5) 2031 (92.4)
Others 7 (1.3) 20 (0.9)
Recipient diabetes status at registration
No 490 (91.1) 1960 (91.5) 0.7*
Yes, insulin dependent 23 (4.3) 77 (3.6)
Yes, noninsulin dependent 25 (4.6) 105 (4.9)
Recipient hypertension at registration
No 434 (81.3) 1743 (81.8) 0.8*
Yes 100 (18.7) 387 (18.2)
Recipient preop cardiac pathology
Congenital heart disease 44 (8.0) 89 (4.0) <0.001*
Coronary artery disease 110 (20.0) 665 (29.9)
Dilated cardiomyopathy 302 (54.8) 1140 (51.2)
Others 95 (17.2) 331 (14.9)
Recipient renal function at transplantation
eGFR ≥ 60 ml/min/1.73 m2 278 (52.3) 1166 (57.4) 0.01*
CKD Stage 3 230 (43.3) 820 (40.3)
CKD Stage 4 21 (4.0) 46 (2.3)
CKD Stage 5 2 (0.4) 1 (0.0)
Urgent status recipient at transplantation 303 (54.9) 547 (24.4) <0.001*
Recipient with VAD prior to transplantation
None 328 (76.1) 1248 (90.2) <0.001*
Left VAD 61 (14.2) 59 (4.3)
Right VAD 9 (2.1) 14 (1.0)
Bilateral VAD 33 (7.6) 62 (4.5)
Recipient on inotrope prior to transplantation 216 (51.2) 532 (39.1) <0.001*
Recipient on IABP prior to transplantation 38 (8.9) 145 (10.5) 0.3*
Recipient on ECMO prior to transplantation 10 (2.4) 6 (0.4) <0.001*
Allograft total ischaemic time (h), mean  SD 3.4  1.2 3.2  1.0 0.001‡
Post-transplant severe PGD 101 (18.3) 53 (2.4) <0.001*
Transplantation era
Era 1995–2000 66 (12.0) 1030 (46.0) <0.001*
Era 2001–2005 83 (15.0) 464 (20.7)
Era 2006–2010 99 (17.9) 309 (13.8)
Era 2011–2017 304 (55.1) 436 (19.5)
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associated with higher short-term mortality rate and
predicts increased risk of developing ESRD in future,
but does not influence long-term survival.
The baseline characteristics of our cohort are compa-
rable to that of other large-scale registry data [2,5,16].
The reported rate of stage 3 AKI requiring RRT in the
postoperative period varies considerably from 3.0% to
34.2% [2,11,17–22]. In addition to variable practice and
criteria for post-transplant RRT utilization adopted by
different centres, this rate appears to have a temporal
trend. For example, the lowest published incidence of
postoperative RRT, 3.0%, came from a cohort operated
between 1990 and 2000 [2], while the highest incidence,
34.2%, was from a cohort operated between 2009 and
2014 [22]. This temporal trend was also observed in
our cohort. Those receiving RRT increased from 12.0%
in the era 1995–2000 to 47.7% in the era 2011–2017.
There are several possible explanations for this. An
urgent list for heart transplantation, aiming to prioritize
the haemodynamically unstable and unwell patients,
who require inotropic and mechanical support,
although introduced in 1999, was only formally imple-
mented with defined clinical criteria in the UK in 2008.
The percentage of recipients who were of urgent status
at transplantation increased dramatically from 1.7% in
the era 1995–2000 to 74.1% in the era 2011–2017. Simi-
larly, the percentage of recipients supported by VADs,
inotropes, IABP and ECMO increased. With more
recipients of higher risk undergoing heart transplanta-
tion, especially those with left and bilateral VADs and
on ECMO, the incidence of postoperative stage 3 AKI
requiring RRT increased [12]. In addition, the donor
criteria had been extended in recent years [23], as
evident in our cohort with the mean donor age rising
continuously over time. Changes in donor and recipient
characteristics are likely to result in a higher risk of
post-transplant haemodynamic instability and complica-
tions including stage 3 AKI requiring RRT. The
increased availability of and easier access to RRT in the
more recent eras may have also contributed to the more
frequent use of RRT in heart recipients.
Apart from transplantation centre and era, donor
age, recipient sex, renal function at transplantation, and
support from left and bilateral VAD and ECMO were
found to be the predictors of stage 3 AKI requiring
RRT. Impaired preoperative renal function had been
recognized as a risk factor for severe AKI post-trans-
plant in several previous studies [19,21,24,25], suggest-
ing that steps to preserve recipients’ renal function
could potentially reduce the risk of stage 3 AKI requir-
ing RRT post-transplant. Heart transplant for recipients
with VAD or on ECMO is of higher risk, leading to
increased likelihood of post-transplant complications,
which are closely associated the requirement of RRT.
The Kaplan–Meier survival curves showed a striking
difference in survival rates over time of the two groups.
The major separation of the two survival curves
occurred in the immediate post-transplant period. Evi-
dence from previous studies showed that severe AKI
was closely associated with other significant complica-
tions, such as tamponade, acute right ventricular failure
and major bleeding, in the immediate postoperative
period [12,22]. Therefore, stage 3 AKI requiring RRT is
often a part of multi-organ failure, which is associated
with very poor short-term prognosis [12,18,19]. Our
data supported this finding, as stage 3 AKI requiring
Table 7. Continued.
RRT group
(N = 552), n (%)
Non-RRT group
(N = 2239), n (%) P-value
Transplantation centre
Centre 1 81 (14.8) 334 (15.0) <0.001*
Centre 2 1 (0.2) 97 (4.4)
Centre 3 91(16.7) 589 (26.4)
Centre 4 129 (23.6) 357 (16.0)
Centre 5 13 (2.4) 87 (3.9)
Centre 6 87 (15.9) 287 (12.9)
Centre 7 111 (20.3) 270 (12.1)
Centre 8 33 (6.0) 207 (9.3)
SD, standard deviation.
*Analysed by chi-squared test.
†
Analysed by Mann–Whitney U-test.
‡
Analysed by independent-samples t-test.
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Table 8. Binary logistic regression for risk factors of early death in recipients with severe PGD.
N
Multivariate Analysis
Odds Ratio 95% CI P-value
Donor sex
Female 146 1.00 – –
Male 214 0.49 0.15–1.65 0.5
Donor age 361 1.03 0.99–1.06 0.1
Recipient sex
Female 94 1.00 – –
Male 267 2.31 0.60–8.91 0.2
Recipient age 361 1.07 1.03–1.11 <0.001
Gender mismatch
No 252 1.00 – –
Male donor to female recipient 29 0.75 0.10–5.83 0.8
Female donor to male recipient 80 0.72 0.08–4.58 0.7
Recipient ethnicity
Asian 28 1.00 – –
Black 9 0.05 0.00–0.72 0.03
White 321 0.61 0.15–2.54 0.5
Others 2 – – –
Recipient diabetes status at registration
No 315 1.00 – –
Yes, insulin dependent 22 1.13 0.21–6.01 0.9
Yes, noninsulin dependent 14 3.74 0.48–29.02 0.2
Recipient hypertension at registration
No 277 1.00 – –
Yes 69 0.40 0.14–1.16 0.09
Recipient preop cardiac pathology
Congenital heart disease 25 1.00 – –
Coronary artery disease 80 0.13 0.01–1.38 0.09
Dilated cardiomyopathy 183 0.12 0.01–1.09 0.06
Others 67 0.13 0.01–1.35 0.09
Recipient renal function at transplantation
eGFR ≥ 60 ml/min/1.73 m2 197 1.00 – –
CKD Stage 3 138 1.16 0.47–2.83 0.8
CKD Stage 4 9 0.95 0.04–22.84 0.9
CKD Stage 5 2 – – –
Urgent status recipient at transplantation 160 0.21 0.06–0.76 0.02
Recipient with VAD prior to transplantation
None 170 1.00 – –
Left VAD 48 0.72 0.23–2.32 0.6
Right VAD 6 0.11 0.01–8.36 0.3
Bilateral VAD 41 4.91 1.21–19.97 0.03
Recipient on inotrope prior to transplantation 101 1.58 0.58–4.31 0.4
Recipient on IABP prior to transplantation 22 6.30 1.27–31.31 0.03
Recipient on ECMO prior to transplantation 13 0.39 0.05–3.28 0.4
Allograft total ischaemic time 341 1.58 1.12–2.22 0.009
Transplantation era
Era 1995–2000 47 1.00 – –
Era 2001–2005 70 0.79 0.08–7.48 0.8
Era 2006–2010 67 1.49 0.15–15.17 0.7
Era 2011–2017 177 0.31 0.03–3.30 0.3
Transplantation centre
Centre 1 61 1.00 – –
Centre 2 2 – – –
Centre 3 45 0.02 0.02–0.66 0.02
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RRT was significantly associated with all of the docu-
mented complications in the immediate post-transplant
periods. In addition, among the recipients who devel-
oped severe PGD post-transplant, those required RRT
was of an increased risk of 90-day mortality. This find-
ing was consistent with that reported by Sabatino et al.
[26]. While severe PGD leads to post-transplant haemo-
dynamic instability and thus higher risk of developing
severe AKI, the requirement of RRT indicates worse sys-
temic morbidity and predicts mortality in the recipients
with severe PGD.
Interestingly, the gap between the two survival curves
gradually reduced over time, indicating that the sub-
group of recipients in the RRT group, who had survived
through the initial post-transplant period, had a lower
subsequent attrition rate. The differences in the charac-
teristics of the 3-month survivors in the RRT and non-
RRT groups could not explain this phenomenon, which
had never been discussed in the literature either. Other
factors that were not considered in this study, such as
frailty [27,28], might shed light on the difference in the
long-term attrition rate between the two groups. We
hypothesized that these recipients in the RRT group,
who survived through the haemodynamic instability
and other major complications in the initial post-trans-
plant period, were perhaps a group of self-selected
patients with better physiological ‘reserve’.
In contrast to most of the studies about peri-operative
renal function and survival [21,29], we found that none
of the renal function-related factors peri-transplant had a
statistical effect on long-term survival. The adverse
impact of stage 3 AKI requiring RRT was purely on the
short-term survival, as shown by the finding of the
Kaplan–Meier survival analysis. This observation reflects
Table 8. Continued.
N
Multivariate Analysis
Odds Ratio 95% CI P-value
Centre 4 97 0.19 0.08–1.63 0.2
Centre 5 1 0.18 0.07–1.64 0.2
Centre 6 49 0.01 0.02–0.50 0.005
Centre 7 62 0.08 0.04–1.21 0.08
Centre 8 37 – – –
Postop severe AKI requiring RRT
No 89 1.00 – –
Yes 268 8.07 2.58–25.20 <0.001
Time 3-month 1-year 5-year 10-year 15-year 20-year
Non-RRT Probability 
(95% CI)
99.9%
(99.7–100%)
99.5%
(99.2–99.8%)
97.4%
(96.7–98.1%)
92.2%
(90.8–93.6%)
86.1%
(84.0–88.2%)
81.6%
(78.7–84.6%)
RRT Probability 
(95% CI)
96.7%
(95.3–98.2%)
94.8%
(93.0–96.7%)
91.2%
(88.6–93.9%)
85.1%
(80.9–89.5%)
73.5%
(65.8–82.1%)
62.8%
(50.6–78.0%)
Figure 3 Kaplan–Meier curves of the freedom from ESRD for the heart transplant recipients in the non-RRT and RRT groups.
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Table 9. Multivariate Cox regression model for time to develop ESRD in patients who survived at least 3 months post-
transplant.
N
Multivariate analysis Final model
Hazard ratio P-value Hazard ratio 95% CI P-value
Recipient sex
Female 627 1.00 –
Male 2204 1.20 0.4
Recipient age 2832 0.99 0.9
Recipient ethnicity
Asian 159 1.00 –
Black 50 3.05 0.06
White 2549 1.12 0.8
Others 27 0.00 1
Recipient diabetes status at registration
No 2487 1.00 – 1.00 – –
Yes, insulin dependent 100 2.41 0.007 2.61 1.44–4.81 0.002
Yes, noninsulin dependent 131 1.24 0.6 1.26 0.61–2.64 0.5
Recipient hypertension at registration
No 2215 1.00 –
Yes 490 0.99 0.9
Recipient preop cardiac pathology
Congenital heart disease 134 1.00 –
Coronary artery disease 786 1.52 0.5
Dilated cardiomyopathy 1462 1.32 0.6
Others 435 1.29 0.7
Recipient renal function at transplantation
eGFR ≥ 60 ml/min/1.73 m2 1465 1.00 – 1.00 – –
CKD Stage 3 1062 2.11 <0.001 2.12 1.45–2.90 <0.001
CKD Stage 4 67 5.02 <0.001 4.81 2.31–9.92 <0.001
CKD Stage 5 3 76.04 <0.001 58.03 6.32–541.01 <0.001
Allograft total ischaemic time 2724 0.85 0.04 0.85 0.72–0.99 0.04
Recipient DeGFR 2576 1.01 <0.001 1.01 1.01–1.02 <0.001
RRT 552
Era 1995–2000
Non-RRT 1030 1.00 – 1.00 – –
RRT 66 1.20 0.6 1.21 0.58–2.51 0.6
Era 2001–2005
Non-RRT 464 0.43 0.001 0.44 0.27–0.71 0.001
RRT 83 – – 1.16 – –
Era 2006–2010
Non-RRT 309 0.42 0.04 0.42 0.19–0.92 0.03
RRT 99 – – 1.66 – –
Era 2011–2017
Non-RRT 436 0.24 0.06 0.23 0.05–0.99 0.05
RRT 304 – – 1.68 – –
Interaction between transplantation era and RRT
Era 1995–2000 and RRT 1.00 – 1.00 – –
Era 2001–2005 and RRT 2.20 0.1 2.20 0.77–6.44 0.1
Era 2006–2010 and RRT 3.30 0.05 3.30 1.02–11.01 0.05
Era 2011–2017 and RRT 6.10 0.05 6.10 1.07–34.03 0.04
Transplantation centre
Centre 1 416 1.00 – 1.00 – –
Centre 2 98 2.91 0.002 3.12 1.58–6.01 0.001
Centre 3 713 0.51 0.05 0.56 0.29–1.08 0.08
Centre 4 489 1.77 0.05 1.77 1.02–3.11 0.04
Centre 5 101 2.20 0.03 2.31 1.12–4.82 0.02
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that in carefully selected heart transplant recipients, their
pretransplant renal function is largely influenced by the
prerenal factors, rather than intrinsic renal pathology.
Despite the lack of influence on long-term survival,
all renal function-related factors, including renal func-
tion at transplantation, DeGFR and stage 3 AKI requir-
ing RRT were significant predictors of ESRD. Moreover,
there was a significant reduction in the risk of develop-
ing ESRD in the non-RRT groups over time. This could
be potentially explained by that in the earlier eras, there
was a proportion of recipients with severe post-trans-
plant renal impairment who did not receive RRT
because of lack of access. They had more rapid renal
decline compared to their peers in the non-RRT groups
who did not have an as significant renal insult in the
immediate post-transplant period. With an increased
availability of RRT in the later eras, most of the recipi-
ents, who would benefit from RRT for renal or other
indications, would have received it and thus belong to
the RRT groups. If this assumption is correct, compared
to that of the era 1995–2000, the non-RRT group in the
era 2011–2017 would include fewer recipients with sig-
nificant post-transplant renal injury. Therefore, the risk
of ESRD for the non-RRT groups decreased with time.
The discrepancy in the risks of developing ESRD
across transplantation centres may be explained by the
different practices, such as immunosuppression strate-
gies and threshold of initiating post-transplant RRT,
adopted by different centres. Unfortunately, with the
limited data available from the registry, we could not
explore this hypothesis further.
The counter-intuitive small protective effect of long
total ischaemic time on renal function deterioration was
first observed by Thomas et al. [3], who reported on
the earlier half of our cohort. With an additional
10 years of data, this effect persists. It is independent of
other variables, such as recipients’ age and cardiac
pathologies. We speculate that with an anticipated long
ischaemic time, the selection of donor hearts would be
more cautious. Therefore, proportionally, there would
be few extended-criteria donor hearts with longer
ischaemic time. Better donor heart quality reduced
recipients’ renal function deterioration in the long term.
Our study benefits from a large national cohort with
long follow-up period and relatively comprehensive data-
base. However, the analysis was limited by the number of
variables collected by the UK Transplant Registry. Some
relevant factors, such as pretransplant proteinuria and
post-transplant immunosuppression therapies, were not
available. As no SCr or eGFR in the immediate post-
transplant period was recorded in the registry, the severity
of post-transplant renal injury not requiring RRT could
not be graded using either the KDIGO classification or
the RIFLE criteria. The use of RRT indicates severe AKI,
but is subject to variation in clinical practice. In addition,
although most of the variables in the registry had less
than 10% missing data, the data about haemodynamic
support required prior to transplantation, including ino-
trope, VAD, IABP and ECMO, were missing in 35.8%
(1205/3365) of recipients.
In conclusion, this study confirmed that stage 3 AKI
requiring RRT post-transplant is a prevalent problem
for heart transplant recipients. It is associated with sig-
nificantly worse short-term survival, but has no impact
on long-term mortality. However, it accelerates renal
function deterioration in the long term. There are two
potential therapeutic gains from this analysis. Optimiz-
ing recipients’ preoperative renal function may help
reduce the risk of severe AKI post-transplant, especially
for male recipients with poor pretransplant renal func-
tion and supported by left VAD or ECMO. In addition,
for recipients who required post-transplant RRT, their
renal function needs to be closely monitored. They are
more likely to benefit from renal-sparing immunosup-
pressive regimes, such as Everolimus instead of the
nephrotoxic Calcineurin inhibitors [30,31].
Authorship
JHD, GP and NS: contributed to the conception and
design of the study. SNR: made substantial contribution
to data acquisition and interpretation. TW and LW:
Table 9. Continued.
N
Multivariate analysis Final model
Hazard ratio P-value Hazard ratio 95% CI P-value
Centre 6 374 2.31 0.008 2.41 1.32–4.31 0.005
Centre 7 381 1.69 0.09 1.66 0.91–3.03 0.1
Centre 8 243 0.88 0.8 0.89 0.42–1.89 0.8
DeGFR, recipient eGFR at transplantation – recipient eGFR at 3-month post-transplant.
Transplant International 2020; 15
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Renal replacement therapy postheart transplantation
performed the statistical analysis. LW: wrote the first
draft of the manuscript. All authors agree to be
accountable for all aspects of the work and resolve any
questions related to the accuracy of the manuscript,
revised the manuscript and approved the final version
of the manuscript.
Fundings
The research was funded by the National Institute for
Health Research (NIHR) Blood and Transplant
Research Unit (BTRU) in Organ Donation and Trans-
plantation at the University of Cambridge in collabora-
tion with Newcastle University and in partnership with
NHSBT. The views expressed are those of the authors
and not necessarily those of the NHS, the NIHR, the
Department of Health or NHSBT.
Conflicts of interests
The authors declare no conflicts of interests.
Acknowledgements
The authors are grateful to all the transplant centres in
the UK, who contributed data on which this article is
based. The authors thank the statisticians at the NHSBT
for their contribution to data acquisition.
REFERENCES
1. Lund LH, Khush KK, Cherikh WS,
et al. The registry of the international
society for heart and lung
transplantation: thirty-fourth adult
heart transplantation report-2017;
focus theme: allograft ischemic time. J
Heart Lung Transplant 2017; 36: 1037.
2. Ojo AO, Held PJ, Port FK, et al.
Chronic renal failure after
transplantation of a nonrenal organ. N
Engl J Med 2003; 349: 931.
3. Thomas HL, Banner NR, Murphy CL,
et al. Incidence, determinants, and
outcome of chronic kidney disease
after adult heart transplantation in the
United Kingdom. Transplantation
2012; 93: 1151.
4. Delgado JF, Crespo-Leiro MG, Gomez-
Sanchez MA, et al. Risk factors
associated with moderate-to-severe
renal dysfunction among heart
transplant patients: results from the
CAPRI study. Clin Transplant 2010;
24: E194.
5. Lund LH, Edwards LB, Dipchand AI,
et al. The registry of the International
Society For Heart and Lung
Transplantation: thirty-third adult
heart transplantation report-2016;
focus theme: primary diagnostic
indications for transplant. J Heart Lung
Transplant 2016; 35: 1158.
6. Smith GL, Lichtman JH, Bracken MB,
et al. Renal impairment and outcomes
in heart failure: systematic review and
meta-analysis. J Am Coll Cardiol 2006;
47: 1987.
7. Gonzalez-Vilchez F, Vazquez de Prada
JA. Chronic renal insufficiency in heart
transplant recipients: risk factors and
management options. Drugs 2014; 74:
1481.
8. Chawla LS, Kimmel PL. Acute kidney
injury and chronic kidney disease: an
integrated clinical syndrome. Kidney
Int 2012; 82: 516.
9. O’Neal JB, Shaw AD, Billings FT.
Acute kidney injury following cardiac
surgery: current understanding and
future directions. Crit Care 2016; 20:
187.
10. Lopez-Delgado JC, Esteve F, Torrado
H, et al. Influence of acute kidney
injury on short- and long-term
outcomes in patients undergoing
cardiac surgery: risk factors and
prognostic value of a modified RIFLE
classification. Crit Care 2013; 17:
R293.
11. Hamour IM, Omar F, Lyster HS,
Palmer A, Banner NR. Chronic kidney
disease after heart transplantation.
Nephrol Dial Transplant 2009; 24:
1655.
12. Garcia-Gigorro R, Renes-Carreno E,
Corres Peiretti MA, et al. Incidence,
risk factors and outcomes of early
acute kidney injury after heart
transplantation: an 18-year experience.
Transplantation 2018; 102: 1901.
13. Do I need NHS REC approval? http://
www.hra-decisiontools.org.uk/ethics/.
14. Levey AS, Coresh J, Greene T, et al.
Using standardized serum creatinine
values in the modification of diet in
renal disease study equation for
estimating glomerular filtration rate.
Ann Intern Med 2006; 145: 247–54.
15. Levey AS, Eckardt KU, Tsukamoto Y,
et al. Definition and classification of
chronic kidney disease: a position
statement from kidney disease:
improving global outcomes (KDIGO).
Kidney Int 2005; 67: 2089.
16. Kobashigawa J, Zuckermann A,
Macdonald P, et al. Report from a
consensus conference on primary graft
dysfunction after cardiac transplantation.
J Heart Lung Transplant 2014; 33: 327.
17. Alam A, Badovinac K, Ivis F, Trpeski
L, Cantarovich M. The outcome of
heart transplant recipients following
the development of end-stage renal
disease: analysis of the Canadian
Organ Replacement Register (CORR).
Am J Transplant 2007; 7: 461.
18. Schiferer A, Zuckermann A, Dunkler D,
et al. Acute kidney injury and outcome
after heart transplantation: large
differences in performance of scoring
systems. Transplantation 2016; 100: 2439.
19. Fortrie G, Manintveld OC, Caliskan K,
Bekkers JA, Betjes MG. Acute kidney
injury as a complication of cardiac
transplantation: incidence, risk factors,
and impact on 1-year mortality and
renal function. Transplantation 2016;
100: 1740.
20. Gude E, Andreassen AK, Arora S, et al.
Acute renal failure early after heart
transplantation: risk factors and
clinical consequences. Clin Transplant
2010; 24: E207.
21. Guven G, Brankovic M,
Constantinescu AA, et al. Preoperative
right heart hemodynamics predict
postoperative acute kidney injury after
heart transplantation. Intensive Care
Med 2018; 44: 588.
22. Ivey-Miranda JB, Flores-Umanzor E,
Farrero-Torres M, Santiago E, Cepas-
Guillen PL, Perez-Villa F. Predictors of
renal replacement therapy after heart
transplantation and its impact on
long-term survival. Clin Transplant
2018; 32: e13401.
16 Transplant International 2020;
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Wang et al.
23. Tjahjono R, Connellan M, Granger E.
Predictors of acute kidney injury in
cardiac transplantation. Transplant
Proc. 2016; 48: 167.
24. Trivedi JR, Cheng A, Ising M, Lenneman
A, Birks E, Slaughter MS. Heart
transplant survival based on recipient
and donor risk scoring: a UNOS
database analysis. ASAIO J 2016; 62: 297.
25. Kolsrud O, Karason K, Holmberg E,
et al. Renal function and outcome
after heart transplantation. J Thorac
Cardiovasc Surg 2018; 155: 1593.
26. Sabatino M, Vitale G, Manfredini V,
et al. Clinical relevance of the
International Society for Heart and
Lung Transplantation consensus
classification of primary graft
dysfunction after heart transplantation:
epidemiology, risk factors, and
outcomes. J Heart Lung Transplant
2017; 36: 1217.
27. Kobashigawa J, Dadhania D, Bhorade
S, et al. Report from the American
Society of Transplantation on frailty in
solid organ transplantation. Am J
Transplant 2019; 19: 984.
28. Bottiger BA, Nicoara A, Snyder LD,
et al. Frailty in the end-stage lung
disease or heart failure patient:
implications for the perioperative
transplant clinician. J Cardiothorac
Vasc Anesth 2019; 33: 1382.
29. Boyle JM, Moualla S, Arrigain S, et al.
Risks and outcomes of acute kidney
injury requiring dialysis after cardiac
transplantation. Am J Kidney Dis 2006;
48: 787.
30. Gude E, Gullestad L, Andreassen AK.
Everolimus immunosuppression for
renal protection, reduction of allograft
vasculopathy and prevention of
allograft rejection in de-novo heart
transplant recipients: could we have it
all? Curr Opin Organ Transplant 2017;
22: 198.
31. Andreassen AK, Andersson B,
Gustafsson F, et al. Everolimus
initiation with early calcineurin
inhibitor withdrawal in de novo heart
transplant recipients: three-year results
from the randomized SCHEDULE
study. Am J Transplant 2016; 16:
1238.
Transplant International 2020; 17
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Renal replacement therapy postheart transplantation
